Patient-reported Outcomes in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Glofitamab Plus Gemcitabine and Oxaliplatin in STARGLO
Publication date: Available online 11 October 2026 Source: Clinical Lymphoma Myeloma and Leukemia Author(s): Gareth P. Gregory, Jeremy S. Abramson, Huiqiang Huang, Qingyuan Zhang, Matthew Ku, Dok Hyun Yoon, Christopher P. Fox, Haifaa Abdulhaq, William Townsend, Joan Ashby, Alana Harris, Estefania Mulvihill, Martine Kallemeijn, Murali Kesavan, Richard Ta, Voleak Choeurng, Linda Lundberg, Huilai Zhang
Patient-reported Outcomes in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Glofitamab Plus Gemcitabine and Oxaliplatin in STARGLO. // Clinical Lymphoma, Myeloma & Leukemia. – URL: https://www.sciencedirect.com/science/article/pii/S2152265026040012?dgcid=rss_sd_all
Patient-reported Outcomes in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Glofitamab Plus Gemcitabine and Oxaliplatin in STARGLO. Clinical Lymphoma, Myeloma & Leukemia. https://www.sciencedirect.com/science/article/pii/S2152265026040012?dgcid=rss_sd_all
“Patient-reported Outcomes in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Glofitamab Plus Gemcitabine and Oxaliplatin in STARGLO.” Clinical Lymphoma, Myeloma & Leukemia.
@article{article88841,
title = {Patient-reported Outcomes in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Glofitamab Plus Gemcitabine and Oxaliplatin in STARGLO},
journal = {Clinical Lymphoma, Myeloma \& Leukemia},
url = {https://www.sciencedirect.com/science/article/pii/S2152265026040012?dgcid=rss_sd_all}
}